Setor K Kunutsor1, Stephan J L Bakker2, Jenny E Kootstra-Ros3, Hans Blokzijl4, Ronald T Gansevoort5, Robin P F Dullaart6. 1. Department of Public Health and Primary Care, University of Cambridge, Cambridge, United Kingdom; School of Clinical Sciences, University of Bristol, Bristol, United Kingdom. Electronic address: skk31@cantab.net. 2. Department of Internal Medicine, University of Groningen and University Medical Center, Groningen, The Netherlands; Top Institute Food and Nutrition, Wageningen, The Netherlands. 3. Department of Clinical Chemistry, University of Groningen and University Medical Center, Groningen, The Netherlands. 4. Department of Gastroenterology and Hepatology, University of Groningen and University Medical Center, Groningen, The Netherlands. 5. Department of Internal Medicine, University of Groningen and University Medical Center, Groningen, The Netherlands. 6. Department of Endocrinology, University of Groningen and University Medical Center, Groningen, The Netherlands.
Abstract
BACKGROUND: Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) have been linked with an increased risk of type 2 diabetes, but their relationships with cardiovascular disease (CVD) are uncertain. We aimed to assess the associations of ALT and AST with CVD risk and determine their potential utility for CVD risk prediction. METHODS: ALT and AST measurements were made at baseline in the PREVEND prospective cohort involving 6899 participants aged 28-75 years without pre-existing CVD. RESULTS: During 10.5 years of follow-up, 729 CVD events were recorded. Serum aminotransferases were strongly correlated with each other and each weakly correlated with several cardiovascular risk markers. ALT and AST were each approximately log-linearly associated with CVD risk. In analyses adjusted for conventional risk factors, the hazard ratios (95% CIs) for CVD per 1 standard deviation increase in loge ALT and loge AST were 0.87 (0.79-0.94; P = 0.001) and 0.91 (0.84-0.98; P = 0.017) respectively. The associations remained consistent after additional adjustment for several potential confounders including alcohol consumption, fasting glucose, and C-reactive protein, with corresponding hazard ratios of 0.88 (0.80-0.96; P = 0.003) and 0.92 (0.84-0.99; P = 0.029). The inverse associations persisted within normal ranges of the aminotransferases. Adding ALT or AST to a CVD risk prediction model containing established risk factors did not improve the C-index or net reclassification. CONCLUSIONS: Available data suggest the liver aminotransferases are each inversely, independently, and approximately log-linearly associated with CVD risk. Nonetheless, they provide no significant improvement in CVD risk assessment beyond conventional CVD risk factors.
BACKGROUND:Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) have been linked with an increased risk of type 2 diabetes, but their relationships with cardiovascular disease (CVD) are uncertain. We aimed to assess the associations of ALT and AST with CVD risk and determine their potential utility for CVD risk prediction. METHODS: ALT and AST measurements were made at baseline in the PREVEND prospective cohort involving 6899 participants aged 28-75 years without pre-existing CVD. RESULTS: During 10.5 years of follow-up, 729 CVD events were recorded. Serum aminotransferases were strongly correlated with each other and each weakly correlated with several cardiovascular risk markers. ALT and AST were each approximately log-linearly associated with CVD risk. In analyses adjusted for conventional risk factors, the hazard ratios (95% CIs) for CVD per 1 standard deviation increase in loge ALT and loge AST were 0.87 (0.79-0.94; P = 0.001) and 0.91 (0.84-0.98; P = 0.017) respectively. The associations remained consistent after additional adjustment for several potential confounders including alcohol consumption, fasting glucose, and C-reactive protein, with corresponding hazard ratios of 0.88 (0.80-0.96; P = 0.003) and 0.92 (0.84-0.99; P = 0.029). The inverse associations persisted within normal ranges of the aminotransferases. Adding ALT or AST to a CVD risk prediction model containing established risk factors did not improve the C-index or net reclassification. CONCLUSIONS: Available data suggest the liver aminotransferases are each inversely, independently, and approximately log-linearly associated with CVD risk. Nonetheless, they provide no significant improvement in CVD risk assessment beyond conventional CVD risk factors.
Authors: Jose L Flores-Guerrero; Maryse C J Osté; Lyanne M Kieneker; Eke G Gruppen; Justyna Wolak-Dinsmore; James D Otvos; Margery A Connelly; Stephan J L Bakker; Robin P F Dullaart Journal: J Clin Med Date: 2018-12-04 Impact factor: 4.241
Authors: Adrian Post; Dion Groothof; Joëlle C Schutten; Jose L Flores-Guerrero; J Casper Swarte; Rianne M Douwes; Ido P Kema; Rudolf A de Boer; Erwin Garcia; Marge A Connelly; Theo Wallimann; Robin P F Dullaart; Casper F M Franssen; Stephan J L Bakker Journal: Clin Endocrinol (Oxf) Date: 2021-01-10 Impact factor: 3.478
Authors: Sara Sokooti; Jose L Flores-Guerrero; Lyanne M Kieneker; Hiddo J L Heerspink; Margery A Connelly; Stephan J L Bakker; Robin P F Dullaart Journal: J Clin Endocrinol Metab Date: 2021-05-13 Impact factor: 5.958
Authors: Jose L Flores-Guerrero; Berend Daan Westenbrink; Margery A Connelly; James D Otvos; Dion Groothof; Irina Shalaurova; Erwin Garcia; Gerjan Navis; Rudolf A de Boer; Stephan J L Bakker; Robin P F Dullaart Journal: Eur J Clin Invest Date: 2020-12-18 Impact factor: 4.686
Authors: Setor K Kunutsor; Julia M Spee; Lyanne M Kieneker; Ron T Gansevoort; Robin P F Dullaart; Albert-Jan Voerman; Daan J Touw; Stephan J L Bakker Journal: J Am Heart Assoc Date: 2018-05-02 Impact factor: 5.501
Authors: Adrian Post; Daan Kremer; J Casper Swarte; Sara Sokooti; Fabian A Vogelpohl; Dion Groothof; Ido P Kema; Erwin Garcia; Margery A Connelly; Theo Wallimann; Robin P F Dullaart; Casper F M Franssen; Stephan J L Bakker Journal: J Hypertens Date: 2022-02-01 Impact factor: 4.844